A Biotech Slump Is Emptying Labs and Threatening Research on New Drugs
Sangamo Therapeutics Inc.’s cost cuts didn’t hurt just the roughly 162 US workers who lost their jobs this
2023-11-22 19:45
Merck Discontinues Developing Drug Candidates With Sichuan Kelun After Daiichi Sankyo Deal
Merck & Co. won’t continue with two drug candidates it previously agreed to co-develop with a Chinese biotech
2023-10-23 13:49
Sage Tumbles as Depression Pill Approval Omits Major Disorder
Sage Therapeutics Inc. slumped in early trading after regulators granted approval to its fast-acting pill only for postpartum
2023-08-07 20:23
Biogen to Buy Reata for $7.3 Billion in Rare-Disease Deal
Biogen Inc. agreed to acquire Reata Pharmaceuticals Inc. for $7.3 billion, including debt, to expand its rare disease
2023-07-28 22:56
Women Hold a Third of S&P 500 Boards Seats With Gains in June
Women retained control of a record high one-third of S&P 500 board seats in June as companies moved
2023-07-28 21:52
Eisai Appoints CEO’s 34-Year-Old Son to Lead Global Alzheimer Drug Program
Japanese drug giant Eisai Co. said global Alzheimer drug program officer Ivan Cheung will retire at the end
2023-07-11 11:19
NATO Summit, Ukraine’s Arms Plan: Your Sunday US Briefing
Hello from Washington, where the dog days of summer have arrived and the unbearable humidity is ensuring DC
2023-07-09 23:59
How a Japanese Drugmaker Clinched Win Over Alzheimer’s
(This story was originally published Sept. 29. On Thursday, the US Food and Drug Administration granted full approval
2023-07-07 08:56
Eisai Alzheimer's Drug Gets Full US Approval, Widening Access to the Therapy
Eisai Co.’s Alzheimer’s drug Leqembi gained full approval from US regulators, a move that will help widen insurance
2023-07-07 08:53